A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab ...

Number 5: The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as interchangeable with Humira, enhancing access to affordable biologics for chronic plaque ...

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes ...

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.

Number 5: Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, ...

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory ...